Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Calcimimetics in Hypophosphatemic Rickets
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Registration Number
- NCT00844740
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
20070360 Incident Dialysis
- Conditions
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 313
- Registration Number
- NCT00803712
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
- Conditions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Papageorgiou General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00446329
- Locations
- 🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00431496
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 360
- Registration Number
- NCT00379899
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
- Conditions
- Interventions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3883
- Registration Number
- NCT00345839
The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects
- Conditions
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2007-07-23
- Lead Sponsor
- Tufts University
- Target Recruit Count
- 17
- Registration Number
- NCT00336739
- Locations
- 🇺🇸
Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 8
- Registration Number
- NCT00195936
- Locations
- 🇺🇸
Section of Pediatric Nephrology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00132431
SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 673
- Registration Number
- NCT00117052
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.